An interventional study of Learning Collaborative in Opioid Use Disorder, Incarcerated Individuals and Methadone Maintenance, sponsored by Brendan Saloner. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Brendan Saloner · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to improve implementation of hospital/clinic methadone in several carceral systems and study the effects of implementation on patient outcomes.
This study has four Aims:
Incarcerated persons have a high prevalence of opioid use disorder (OUD), and risk of fatal and nonfatal overdose surges immediately following release. Providing medications for OUD (MOUD) during and following incarceration is a proven strategy for reducing overdose risk, yet few facilities offer MOUD. Of the three MOUDs approved by the Food and Drug Administration, methadone is particularly challenging for carceral facilities to provide because it typically can be dispensed only by federally-accredited and certified opioid treatment programs (OTPs). Very few carceral facilities have created onsite OTPs, citing the costly, time-intensive process as a barrier to uptake. Other facilities do not provide methadone or offer limited methadone through partnerships with community-based OTPs. This is often not feasible in rural areas without OTPs, where many carceral facilities are located. Expanding access to carceral methadone is of key public health importance, because it is the optimal treatment for some patients, particularly those with high opioid tolerance associated with use of fentanyl and its analogs.
In 2024, the Substance Abuse and Mental Health Services Administration (SAMHSA) released updated 42 CFR Part 8 rules, which clarified that any carceral facility registered as a "hospital/clinic" with the Drug Enforcement Administration (DEA) is permitted to stock and dispense methadone for the treatment of OUD, as long as the patient is primarily being treated for another medical condition. Given the high prevalence of comorbidities and the opportunity to provide methadone outside of OTPs, the hospital/clinic designation could dramatically expand access to MOUD for incarcerated persons. However, implementation also requires carceral systems to engage with potentially unfamiliar processes, such as applying for the hospital/clinic designation, stocking and dispensing methadone, and initiating and maintaining methadone treatment. Through a technical assistance partnership with our team, three state departments of corrections (DOCs) - Colorado, Delaware, and Washington - are the first jurisdictions to implement the hospital/clinic designation for this purpose, each at different stages of implementation. Given the recency of the hospital/clinic designation rules, there is need to understand how these vanguard DOCs are implementing, how adoption affects OUD-related outcomes during and after incarceration, and the cost-effectiveness of this process, all of which can inform future adoption of this novel approach for methadone provision.
Working in partnership with these vanguard DOCs, the overarching goal of this five-year JCOIN project is to generate research evidence that can support the broader implementation of methadone in carceral facilities using the hospital/clinic designation. We will conduct a mixed-methods study that engages early adopter facilities in a learning collaborative that will blend didactic education and applied problem-solving, evaluating implementation outcomes via surveys and qualitative interviews (Aim 1). We will use 2022-2028 carceral health records from all three vanguard DOCs to study OUD-related outcomes during incarceration (Aim 2). We will link carceral health records with post-release Medicaid data in the Washington DOC to examine post-release OUD outcomes (Aim 3) and conduct a cost-effectiveness evaluation (Aim 4). Our study is guided by the substance use treatment framework, the Behavioral Cascade of Care, and the implementation outcomes framework, RE-AIM. Our study aims are as follows:
Aim 1: Engage early implementers in a learning collaborative to improve reach, adoption, and implementation of the hospital/clinic designation. Hypothesis: The learning collaborative will improve the reach and adoption of methadone via the hospital/clinic designation and help navigate potential challenges, such as stigma towards MOUD, establishing methadone stocking and dispensing protocols, staffing, reentry planning and coordination between security and medical staff.
Aim 2: Identify the effect of the hospital/clinic designation on initiation and retention for MOUD treatment during incarceration. Hypothesis: The hospital/clinic designation will result in improved overall initiation and retention of MOUD in the Colorado, Delaware and Washington DOCs.
Aim 3: Examine the effect of the hospital/clinic designation on post-release care for opioid use disorder and chronic health conditions. Hypothesis: Use of the hospital/clinic designation will result in improved post-release use of methadone and chronic condition management, and decreased incidence of overdose in the year following release. Effects will vary by reentry county characteristics.
Aim 4: Calculate the cost, cost-effectiveness, and budgetary impact of carceral methadone treatment delivered via the hospital/clinic designation. Hypothesis: Use of the hospital/clinic designation will be cost-effective and affordable within the resources of each DOC compared to the status quo where methadone is only obtained from OTPs.
Study results will inform decisions about current and future adoption of this important new option for expanding methadone access in carceral facilities, with the potential to have huge lifesaving effects on a marginalized population.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
This study's planned enrollment of 30 is below the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Browse Opioid-Related Disorders studies →This is the only study on the registry with Brendan Saloner as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All participants will receive individual and group coaching sessions
Other: Learning Collaborative
All participants will receive individual and group coaching sessions to facilitate implementation of the hospital/clinic designation.
Patients on methadone through h/c
Number of patients receiving methadone via the hospital/clinic designation
Time frame: At baseline, at month 12, and at month 24
Implementation outcomes assessment
Implementation Outcomes Assessment from Weiner et al., 2017. doi:10.1186/s13012-017-0635-3. The three measures from this assessment will be combined into one measure.
Time frame: At baseline, at month 12, and at month 24
Staff Attitudes Towards MOUD
Knudsen et al., 2005's Staff Attitudes Towards MOUD measure. doi:10.1016/j.jsat.2005.05.002
Time frame: At baseline, at month 12, and at month 24
Organizational Readiness for Implementing Change
Shea et al., 2014's Organizational Readiness for Implementing Change measure. doi:10.1186/1748-5908-9-7
Time frame: At baseline, at month 12, and at month 24
No study locations are listed for this record.
Plan to share: Yes — For participants who consent to data sharing, de-identified survey and interview data will be deposited into the HEAL data repository.
Supporting information: Study protocol, Informed consent form, Analytic code
Start is estimated for Jun 2027; primary completion for Sep 2029, 27 months later.
Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 27 months is close to that.
Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Sep 2026 → Jun 2027 and primary completion Sep 2028 → Sep 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.